OS Therapies Delays Q2 2025 Financial Report

OS Therapies Incorporated ( (OSTX) ) has released a notification of late filing.

OS Therapies Incorporated has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for the delay is the additional time required to complete the financial statement close process, which could not be achieved without unreasonable effort or expense. The company anticipates filing the report within the five-day extension period allowed under Rule 12b-25. No significant changes in financial results are expected compared to the corresponding period last year, and the company remains committed to compliance with all filing requirements. The notification was signed by Paul Romness, the Chief Executive Officer.

The most recent analyst rating on (OSTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.

Spark’s Take on OSTX Stock

According to Spark, TipRanks’ AI Analyst, OSTX is a Underperform.

OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company’s financial instability and negative market sentiment.

To see Spark’s full report on OSTX stock, click here.

More about OS Therapies Incorporated

Average Trading Volume: 504,004

Technical Sentiment Signal: Buy

Current Market Cap: $67.99M

For a thorough assessment of OSTX stock, go to TipRanks’ Stock Analysis page.